

Please type a plus sign (+) inside this +

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	
Sheet 1	of 1	Filing Date	11-09-2001
		First Named Inventor	Anne Chew
		Group Art Unit	1646
		Examiner Name	Prema Mertz
		Attorney Docket Number	MWH-0002US2

11/09/01
11/09/01
11/09/01

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AS	BA	PRITCHARD MA ET AL., "The Interleukin-4 Receptor gene (IL4R) maps to 16p11.2-16p12.1 in human and to the distal region of mouse chromosome 7," Genomics, Vol. 10 (No. 3), p. 801-806, (July 1991).
	BB	DEICHMANN K. ET AL., "Common Polymorphisms in the Coding Part of the IL4-Receptor Gene," Biochem Biophys Res Comm, Academic Press, Vol. 231 (No. 3), p. 696-697, (February 24, 1997).
	BC	KURANA HERSHY GK ET AL., "The Associations of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor," New Eng. J. Med, Vol. 337 (No. 24), p. 1720-25, (December 11, 1997).
	BD	IMANI F ET AL., "Interleukin-4 (IL-4) Induces Phosphatidylinositol 3-kinase (p85) Dephosphorylation. Implications for the role of SHP1-1 in the IL-4-induced signals in human B cells," J. Biol. Chem., Vol. 272 (no. 12) p. 7927-7931, (March 21, 1997).
	BE	MITSUBASU H. ET AL., "Ile50Val variant of IL4Ralpha upregulates IgE synthesis and associates with atopic asthma," Nat Genet, Vol. 19 (No. 2), p. 119-120, (June 1998).
	BF	BUETOW KH ET AL., "Reliable identification of large numbers of candidate SNPs from public EST data," Nat Genet, Vol. 21 (No. 3), p. 323-325, (March 1999).
✓	BG	KANEMITSU S. ET AL., "Association of Interleukin-4 receptor and Interleukin-4 promoter gene polymorphisms with systemic lupus erythematosus," Arthritis Rheum, American College of Rheumatology, Vol. 42 (No. 6), p. 1298-1300, (June 1999).
AS	BH	KRUSE S. ET AL., "The Polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction," Immunology, Blackwell Science Ltd, Vol. 96 (No. 3), p. 365-71, (March 1999).

Examiner Signature	<i>G. Mertz</i>	Date Considered	7/19/03
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box.

+

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	100-000000000
		Filing Date	11-09-2001
		First Named Inventor	Anne Chew
		Group Art Unit	1646
		Examiner Name	Prema Mertz
		Attorney Docket Number	MWH-0002US2
Sheet	1	of	1

Examiner Signature		Date Considered	7/9/03
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/010,802
Sheet	1	Filing Date	11/09/2001
of 3		First Named Inventor	A. Chew
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	MWH-0002US2
		MAY 20 2002 U.S. PATENT AND TRADEMARK OFFICE	RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
AS	DA	BACANU S-A, DEVLLIN B & ROEDER K, "The Power of Genomic Control," Am. J. Hum. Genet., Vol. 66, p. 1933-44, (May 11, 2000).		
	DB	BAILEY DS, BONDAR A & FURNESS LM, "Pharmacogenomics-It's not just pharmacogenetics," Curr Opin in Biotech, Vol 9, p. 595-601, (1998).		
	DC	BERTILSSON L, DAHL M-L, TYBRING G, "Pharmacogenetics of antidepressants: clinical aspects," Acta Psychiatr Scand, Vol 96 (Suppl 391), p. 14-21, (1997).		
	DD	CHAKRAVARTI A, "Population genetics-making sense out of sequence," Nature genetics, Vol 21, p. 56-60, (January 1999).		
	DE	CHAKRAVARTI A, "It's raining SNPs, hallelujah?," Nature genetics, Vol. 19, p. 216-7, (July 1998).		
	DF	CLARK AG et al., "Haplotype Structure and Population Genetic Inferences from Nucleotide-Sequence Variation in Human Lipoprotein Lipase," Am J Hum Genet, Vol 63, p. 595-612, (July 29, 1998).		
	DG	COHEN J, "Medicine: Developing prescriptions with a personal touch," Science, Vol 275, p. 776, (February 7, 1997).		
	DH	HILL AVS et al., "Human genetic variation and its impact on public health and medicine , Evolution in Health and Disease, Stearns S. (Ed.), Oxford University Press (New York), p. 62-74, (1999).		
	DI	JUDSON R, STEPHENS JC & WINDEMUTH A, "The predictive power of haplotypes in clinical response," Pharmacogenomics, Vol. 1 (No. 1), p. 1-12, (2000).		
AS	DJ	KALOW W, OZDEMIR V, TANG B-K, TOTHFALUSI L & ENDRENYI L, "The Science of pharmacological variability: An essay," Clin Pharmacol Ther, Vol. 66, p. 445-7, (November 1999).		
AS	DK	KLEYN PW & VESELL ES, "Pharmacogenomics: Genetic Variation as a Guide to Drug Development," Science, Vol 281, p. 1820-1, (September 18, 1998).		

Examiner Signature	<i>J. Smith</i>	Date Considered	7/9/03
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box +


PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Approved for use through 10/31/93. OMB 055-003-003-1
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/010,802
		Filing Date	11/09/2001
		First Named Inventor	A. Chew
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	MWH-0002US2
Sheet	3	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	7/9/03
-----------------------	---	--------------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/010,802
				Filing Date	11/09/2001
				First Named Inventor	A. Chew
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	MWH-0002US2

RECEIVED
EPO CENTER 180/280

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AS	DL	KOLA I, "Complex traits, genes, polymorphisms and the drug discovery/development process," Curr Opin in Biotech, Vol 10., p. 589-92, (1999).			
	DM	KWOK P-Y & GU Z, "Single Nucleotide polymorphism libraries: why and how are we building them?," Mol Med Today, Vol. 5, p. 538-43, (December 1999).			
	DN	LU AYH, "Drug-Metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety," Drug Metab & Disposition, Vol. 26 (No. 12), p. 1217-1222, (1998).			
	DO	MARSHALL A, "Getting the right drug into the right patient," Nature Biotechnology, Vol 15, p. 1249-52, (November 1997).			
	DP	MARSHALL E, "Drug Firms to create public database of genetic mutations," Science, Vol 284, p. 406-7, (April 16, 1999).			
	DQ	MEYER UA, "Medically relevant genetic variation of drug effects," Evolution in Health and Disease, Stearns S. (Ed.), Oxford University Press (New York), p. 41-49, (1999).			
	DR	PRITCHARD JK, STEPHENS M, ROSENBERG NA & DONNELLY P, "Association mapping in structured populations," Am J Hum Genet, Vol. 67, p. 170-181, (May 26, 2000).			
	DS	ROSES AD, "Pharmacogenetics and the practice of medicine," Nature, Vol. 405, p. 857-65, (June 15, 2000).			
	DT	STEPHENES JC, "Single-nucleotide polymorphisms , haplotypes, and their relevance to pharmacogenetics," Mol Diagnosis, Vol. 4 (No. 4), p. 309-317, (1999).			
↓	DU	ULBRECHT M, HERGETH MT, WIST M, HEINRICH J, BICKEBOLLER H, WICHMANN H-E & WEISS EH, "Association of beta-2-adrenoreceptor variants with bronchial hyperresponsiveness," Am J Respir Crit Care Med, Vol. 161, p. 469-474, (2000).			
↓	DV	WANG DG ET AL., "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome," Science, Vol. 280, p. 1077-82, (May 15, 1998).			

Examiner Signature	<i>[Signature]</i>	Date Considered	7/9/03
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number 10/010,802 Filing Date 11/09/2001 First Named Inventor A. Chew Group Art Unit 1614 Examiner Name Attorney Docket Number MWH-0002US2	RECEIVED TECH CENTER 1600
Sheet	1	of	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	7/9/03
--------------------	--	-----------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.